Eris Lifesciences Limited

NSEI:ERIS Stock Report

Market Cap: ₹188.7b

Eris Lifesciences Past Earnings Performance

Past criteria checks 2/6

Eris Lifesciences has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 15.7% per year. Eris Lifesciences's return on equity is 12.2%, and it has net margins of 16.9%.

Key information

5.9%

Earnings growth rate

6.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate15.7%
Return on equity12.2%
Net Margin16.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30
Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 10
Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year

Nov 23
Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year

Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?

Oct 22
Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?

Revenue & Expenses Breakdown

How Eris Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:ERIS Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2422,4693,8034,3230
31 Mar 2419,9133,9204,2170
31 Dec 2318,4063,8643,9580
30 Sep 2317,7503,8563,8410
30 Jun 2317,2983,8243,7210
31 Mar 2316,6183,8223,5480
31 Dec 2215,6633,9703,3620
30 Sep 2214,7663,9593,1040
30 Jun 2213,7463,9402,7730
31 Mar 2213,2624,0612,6220
31 Dec 2112,9933,9412,5720
30 Sep 2112,7633,8342,5530
30 Jun 2112,4823,7282,3770
31 Mar 2111,9263,5512,4390
31 Dec 2011,6253,4322,7900
30 Sep 2011,1923,1652,7170
30 Jun 2010,7443,0152,1560
31 Mar 2010,5822,9652,3170
31 Dec 1910,2522,9432,5200
30 Sep 1910,1193,1102,4700
30 Jun 199,9203,0361,8870
31 Mar 199,6722,9082,4530
31 Dec 189,8512,9252,3040
30 Sep 189,4422,8702,2580
30 Jun 189,2122,9451,7080
31 Mar 188,1962,9412,0270
31 Dec 178,0262,8001,9310
30 Sep 177,7812,7351,8180
30 Jun 177,2772,5051,7870
31 Mar 177,2052,4681,7370
31 Mar 165,9671,1121,7460
31 Mar 155,4568921,6320
31 Mar 145,0887041,6640

Quality Earnings: ERIS has high quality earnings.

Growing Profit Margin: ERIS's current net profit margins (16.9%) are lower than last year (22.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ERIS's earnings have grown by 5.9% per year over the past 5 years.

Accelerating Growth: ERIS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ERIS had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.2%).


Return on Equity

High ROE: ERIS's Return on Equity (12.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies